Modalis Issues FY2025 Report With Strict Confidentiality and Risk Disclaimers

Modalis Therapeutics Corporation ( (JP:4883) ) has provided an update.

Modalis Therapeutics Corporation released an English reference version of its business and financial report for the fiscal year ending in 2025, dated February 12, 2026, clarifying that the Japanese version remains the authoritative document. The company emphasizes that the materials are for informational purposes only, are confidential, and may not be reproduced or redistributed without prior written consent, underscoring tight control over the dissemination of its financial and operational disclosures.

The report includes a detailed disclaimer that it does not constitute an offer or solicitation to buy or sell securities in Japan, the U.S. or elsewhere and that the information may change without notice. Modalis further notes that any forward-looking statements are subject to significant risks and uncertainties, disclaims responsibility for third‑party data included, and explicitly rejects any obligation to update or correct the information, signaling a cautious stance toward investor expectations and legal exposure.

The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.

More about Modalis Therapeutics Corporation

Modalis Therapeutics Corporation, listed on the Tokyo Stock Exchange under ticker 4883, operates in the biotechnology and pharmaceutical sector. The company focuses on developing innovative therapeutic solutions, likely centered on advanced genetic or molecular technologies, targeting unmet medical needs in Japan and potentially global markets.

Average Trading Volume: 837,280

Technical Sentiment Signal: Sell

Current Market Cap: Yen4.99B

Learn more about 4883 stock on TipRanks’ Stock Analysis page.